Market Overview

Sanofi, Regeneron Begin Enrollment in CV Outcomes Trial with PCSK9 Antibody for Hypercholesterolemia

Share:
Related SNY
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Here's What Medivation Said In Its Rejection Letter To Sanofi
Sanofi's (SNY) CEO Olivier Brandicourt on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)
Related REGN
The Stocks That Moved The S&P, Dow And Nasdaq Today
Mid-Afternoon Market Update: Crude Oil Down 3.5%; Tesla Shares Rise Following Model 3 Launch

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients. SAR236553/REGN727 is an investigational subcutaneously administered, fully-human antibody that is being evaluated for its impact on lowering low-density lipoprotein cholesterol (LDL-C) by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

The ODYSSEY OUTCOMES trial will enroll approximately 18,000 patients, who recently suffered an acute coronary syndrome (ACS), from 49 countries across six continents. With the start of this study, eleven trials are now recruiting in the global SAR236553/REGN727 Phase 3 program.

Posted-In: News FDA

 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!